This trial is designed to evaluate both intravenous and oral formulations of CK-1827452 in patients with ischemic cardiomyopathy and angina. The primary objective of this trial is to assess the effect of intravenous CK-1827452 on symptom-limited treadmill exercise tolerance. The secondary objectives of this trial are to assess the tolerability and resulting plasma concentrations of CK-1827452 administered as an oral formulation.
CK-1827452 is the subject of a collaboration and option agreement between Cytokinetics and Amgen.
Andrew Wolff, senior vice president of clinical R&D and chief medical officer of Cytokinetics, said: “This trial is another step towards a fuller understanding and characterization of the safety and tolerability of CK-1827452 in patients with heart failure, in this case specifically patients with ischemic cardiomyopathy and angina.”